רווח לפני תשלום ריבית, מסים ופחת: TG Therapeutics (TGTX)

The successful launch of Briumvi has transformed years of R&D expenditures into a high-margin business with low synthesis costs for TG Therapeutics, Inc. (TGTX). The EBITDA_Co trend clearly confirms the company's ability to generate real value, while 192.67 illustrates the level of this metric. Demand for multiple sclerosis therapy remains independent of economic cycles, and the drug's high efficacy ensures a rapid capture of market share.

Investors are assessing the margin of safety for TG Therapeutics, Inc. (TGTX) through net operating cash flow before interest and taxes, which determines the business's actual capacity for self-financing. The expansion of the drug portfolio for the treatment of oncohematology and multiple sclerosis mitigates risks, while the underlying EBITDA confirms the resilience of this biotech model during periods of market volatility.